Haematology

• 

  All Medical News

  ISH / BSH 2016: A well attended joint ISH / BSH meeting in Glasgow brought together cutting edge research from both the UK and international myeloma community, whilst allowing lively debate on how best to implement recent advances within the environment of the NHS. Professor Paul G. Richardson (Boston, USA) and Professor Graham Jackson (Newcastle-Upon-Tyne, UK) give an international and British perspective on highlights from the meeting.

  Written by Lorraine Carolan | 30 May 2016

• 

  All Medical News

  ISH / BSH 2016: Professor John Radford (The University of Manchester), Dr Graham Collins (Oxford University Hospitals) and Professor David Linch ( University College Hospital, London) give their highlights from this year’s BSH meeting in association with the 36th World Congress of the International Society of Hematology.

  Written by Lorraine Carolan | 30 May 2016

• 

  All Medical News

  Clot-buster lowers death risk in deadliest stroke

  Written by Bruce Sylvester | 1 Mar 2016

  by Bruce Sylvester: Tissue plasminogen activator (tPA) treatment with the clot-busting drug alteplase appears to be an effective way to decrease mortality in intraventricular hemorrhage, a catastrophic type… read more.

• 

  All Medical News

  ASH 2015: Building good combinations. Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) discusses the benefits of building good combinations early on in therapy and the impact that newly available triplet oral therapy will have on patients with myeloma

  Written by Lorraine Carolan | 15 Feb 2016

• 

  All Medical News

  ASH 2015: Good news for patients from ASH! Erik Low (Chief Executive Myeloma UK), Professor Antonio Palumbo (University of Torino, Italy), Professor Paul Richardson (Harvard Medical School, Boston, USA) and Dr Shaji Kumar (Mayo Clinic, Rochester, USA) discuss the things they will take home to their myeloma patients folloing ASH 2015

  Written by Lorraine Carolan | 12 Feb 2016

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. CDF changes affecting myeloma patients. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Erik Low (Chief Executive Myeloma UK) discuss recent changes in the CDF and how they affect myeloma patients.

  Written by Lorraine Carolan | 11 Feb 2016

• 

  All Medical News

  ASH 2015: We ask Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA) what the role of PET/CT is as a measure of MRD post ASCT and ask Professor Antonio Palumbo (University of Torino, Italy) and Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) whether MRD measurement is ready for clinical use

  Written by Lorraine Carolan | 10 Feb 2016

  Role of minimal residual disease in treatment tailoring divides experts by Thomas R. Collins Minimal residual disease (MRD) is a guide for tailoring multiple myeloma whose time has… read more.

• 

  All Medical News

  ASH 2015: Video Interview by Esther Drain. Myeloma XI initial response data at ASH. Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) discusses the initial response data from Myeloma XI and whether early intensive therapy is the way forward in managing myeloma, with comment also from Professor Sagar Lonial (Emory University School of Medicine, Atlanta, USA).

  Written by Lorraine Carolan | 9 Feb 2016

• 

  All Medical News

  ASH 2015: Ernest Beutler Lecture Prize: Award-winners trace history of proteasome and its starring role in MM treatment: Interview with Alfred Goldberg, PhD, Professor of Cell Biology at Harvard Medical School, and Paul Richardson, MD, Professor of Medicine at the Dana-Farber Cancer Center

  Written by Lorraine Carolan | 8 Feb 2016

  by Thomas R. Collins: Standing at the center of a decade and a half of stunning advancements in the treatment of multiple myeloma is the ubiquitin proteasome pathway… read more.

• 

  All Medical News

  ASH 2015: Myeloma X (intensive) trial update: Professor Gordon Cook (Leeds Teaching Hospitals, UK) gives an update on Myeloma X and discusses the role of transplant in myeloma in the age of novel agents

  Written by Lorraine Carolan | 5 Feb 2016

• 

  All Medical News

  ASH 2015: Professor Antonio Palumbo (University of Torino, Italy), Dr Shaji Kumar (Mayo Clinic, Rochester, USA), Professor Graham Jackson (NCCC, Newcastle Hospitals Trust, UK) and Professor Gordon Cook (Leeds Teaching Hospitals, UK) give their highlights.

  Written by Lorraine Carolan | 4 Feb 2016

• 

  All Medical News

  ASH 2015 Video Interview by Esther Drain: Association of gene expression profiling, Interim PET, EBV status and PD-L1 expression in cHL. An interview with Dr Cathy Burton (Clinical Haematologist, Leeds Teaching Hospitals, UK)

  Written by Lorraine Carolan | 27 Jan 2016